Government-Owned Inventions; Availability for Licensing, 79348 [2015-31890]
Download as PDF
<![CDATA[
79348
Federal Register / Vol. 80, No. 244 / Monday, December 21, 2015 / Notices
TOTAL ESTIMATED ANNUALIZED BURDEN—HOURS
Number of
respondents
Form name
Number of
responses per
respondent
Total
responses
Average
burden per
response
(in hours)
Total burden
hours
Form 1: Demographic, Service Utilization, and Clinical Indicators Data ....................................................................
Form 2: Performance and System Outcome Benchmark
Data ..................................................................................
56
1
56
425
23,800
56
1
56
425
23,800
Total ..............................................................................
56
........................
56
........................
47,600
Jackie Painter,
Director, Division of the Executive Secretariat.
[FR Doc. 2015–31936 Filed 12–18–15; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 209 and 37 CFR part 404 to
achieve expeditious commercialization
of results of federally-funded research
and development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
U.S. patent applications listed below
may be obtained by emailing the
indicated licensing contact at the
National Heart, Lung, and Blood, Office
of Technology Transfer and
Development Office of Technology
Transfer, 31 Center Drive Room 4A29,
MSC2479, Bethesda, MD 20892–2479;
telephone: 301–402–5579. A signed
Confidential Disclosure Agreement may
be required to receive copies of the
patent applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
Fluorescent Nanodiamonds as Fiducial
Markers for Microscopy
Description of Technology
The invention relates to fluorescent
nanodiamonds (FNDs) and their uses as
fiducial markers for microscopy. FNDs
are bright fluorescent probes that do not
blink or bleach and have broad
VerDate Sep<11>2014
17:38 Dec 18, 2015
Jkt 238001
fluorescence excitation and emission
peaks. The fluorescence intensity can be
readily controlled by the size of the
FND, the number of fluorescent centers
produced in the nanodiamonds, or in
situ through the application of a weak
magnetic field. The particular advantage
of the FND compositions of this
invention are that they are particularly
useful for extended imaging of a single
sample over time periods that can be as
long as a week or more. In an exemplary
embodiment, FNDs are immobilized in
a substrate that are coated with an inert
top coating, like silicon dioxide, or
transparent polymer (e.g. poly-L-lysine,
poly-L-arginine, or siloxanes).
Generally, any suitable methods known
for surface functionalization of the
substrate can be used to make the
composition. In another aspect of this
invention, the inventors designed
software for super-resolution imaging
correction method is employed to
precisely determine the position
coordinates of each of a set of FNDs in
a plurality of images by using Gaussian
fitting of the point spread function
comprises each of the FNDs in the
plurality of images. The calculated
correction is then used to displace each
image to align the coordinates of the
FNDs. The positions of the FNDs can be
tracked with sub-nanometer precision
and residual drift can be reduced to the
nanometer scale over hundreds of hours
of tracking.
Potential Commercial Applications
• Fluorescent Microscopy
• Super-resolution microscopy
• Correlative imaging techniques
combing fluorescence microscopy
with electron, x-ray, or atomic force
microscopy imaging modalities
Competitive Advantages
•
•
•
•
•
Non-blinking, Non-bleaching
Chemically inert
Chemically and physically stable
Broad excitation
Longevity
Development Stage
• In vitro data
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
Inventors
• Keir Neuman, Ambika Bumb, Han
Wen, Jennifer Hong and Susanta
Sarkar (all of NHLBI)
• Chang Yi, Lawrence Samelson, Asit
Manna (all of NCI)
Intellectual Property: HHS Reference
No. E–217–2015/0–US–01
• US Provisional Patent Application 62/
262,058 filed December 2, 2015.
Licensing Contact: Michael
Shmilovich, Esq, CLP; 301–435–5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity:
The National Heart, Lung and Blood
Institute seeks statements of capability
or interest from parties interested in
collaborative research to further develop
and evaluate metallic nanoparticle
vesicles for cancer phototherapy. For
collaboration opportunities, please
contact Vincent Kolesnitchenko, Ph.D.
at kolesniv@nhlbi.nih.gov.
Dated: December 15, 2015.
Michael Shmilovich,
Senior Licensing and Patenting Manager,
National Heart, Lung, and Blood Institute,
Office of Technology Transfer and
Development.
[FR Doc. 2015–31890 Filed 12–18–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Submission for OMB Review; 30-Day
Comment Request; Generic Clearance
for the Collection of Qualitative
Feedback on Agency Service Delivery
(NIAID)
Under the provisions of
Section 3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National
Institutes of Health, has submitted to the
Office of Management and Budget
(OMB) a request for review and
approval of the information collection
listed below. This proposed information
collection was previously published in
the Federal Register on October 1, 2015,
80 FR 59168 and allowed 60-days for
SUMMARY:
E:\FR\FM\21DEN1.SGM
21DEN1
]]>Agencies
[Federal Register Volume 80, Number 244 (Monday, December 21, 2015)]
[Notices]
[Page 79348]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-31890]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the U.S. patent applications listed below may be obtained by emailing
the indicated licensing contact at the National Heart, Lung, and Blood,
Office of Technology Transfer and Development Office of Technology
Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-2479;
telephone: 301-402-5579. A signed Confidential Disclosure Agreement may
be required to receive copies of the patent applications.
SUPPLEMENTARY INFORMATION: Technology description follows.
Fluorescent Nanodiamonds as Fiducial Markers for Microscopy
Description of Technology
The invention relates to fluorescent nanodiamonds (FNDs) and their
uses as fiducial markers for microscopy. FNDs are bright fluorescent
probes that do not blink or bleach and have broad fluorescence
excitation and emission peaks. The fluorescence intensity can be
readily controlled by the size of the FND, the number of fluorescent
centers produced in the nanodiamonds, or in situ through the
application of a weak magnetic field. The particular advantage of the
FND compositions of this invention are that they are particularly
useful for extended imaging of a single sample over time periods that
can be as long as a week or more. In an exemplary embodiment, FNDs are
immobilized in a substrate that are coated with an inert top coating,
like silicon dioxide, or transparent polymer (e.g. poly-L-lysine, poly-
L-arginine, or siloxanes). Generally, any suitable methods known for
surface functionalization of the substrate can be used to make the
composition. In another aspect of this invention, the inventors
designed software for super-resolution imaging correction method is
employed to precisely determine the position coordinates of each of a
set of FNDs in a plurality of images by using Gaussian fitting of the
point spread function comprises each of the FNDs in the plurality of
images. The calculated correction is then used to displace each image
to align the coordinates of the FNDs. The positions of the FNDs can be
tracked with sub-nanometer precision and residual drift can be reduced
to the nanometer scale over hundreds of hours of tracking.
Potential Commercial Applications
Fluorescent Microscopy
Super-resolution microscopy
Correlative imaging techniques combing fluorescence microscopy
with electron, x-ray, or atomic force microscopy imaging modalities
Competitive Advantages
Non-blinking, Non-bleaching
Chemically inert
Chemically and physically stable
Broad excitation
Longevity
Development Stage
In vitro data
Inventors
Keir Neuman, Ambika Bumb, Han Wen, Jennifer Hong and Susanta
Sarkar (all of NHLBI)
Chang Yi, Lawrence Samelson, Asit Manna (all of NCI)
Intellectual Property: HHS Reference No. E-217-2015/0-US-01
US Provisional Patent Application 62/262,058 filed December 2,
2015.
Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity: The National Heart, Lung and
Blood Institute seeks statements of capability or interest from parties
interested in collaborative research to further develop and evaluate
metallic nanoparticle vesicles for cancer phototherapy. For
collaboration opportunities, please contact Vincent Kolesnitchenko,
Ph.D. at kolesniv@nhlbi.nih.gov.
Dated: December 15, 2015.
Michael Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood
Institute, Office of Technology Transfer and Development.
[FR Doc. 2015-31890 Filed 12-18-15; 8:45 am]
BILLING CODE 4140-01-P
